Navigation Links
MADIT-CRT Trial Meets Primary Endpoint
Date:6/23/2009

dvances in indications in the CRM space through trials like MADIT-CRT. More than 80 percent of U.S. patients who receive an ICD or CRT-D were first indicated for this therapy by a clinical trial sponsored by Boston Scientific or its predecessors(3)."

MADIT-CRT is providing insight into the potential of CRT-D therapy to intervene earlier in the natural progression of heart failure. Currently, patients must be in NYHA Class III/IV heart failure to be indicated for CRT-D therapy. However, approximately 70 percent of all heart failure patients in the U.S. fall into Class I or II. Nearly 22 million people worldwide, including approximately 5.5 million Americans, suffer from some form of heart failure.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projec
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture (EDC) Clinical Trial Survey
2. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
3. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
4. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
5. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
6. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
7. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
8. New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases
9. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
10. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
11. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
(Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
Breaking Medicine Technology:Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
... Calif., March 7, 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ... 1 study of ISIS-STAT3Rx, a Generation 2.5 antisense drug ... of signal transducer and activator of transcription 3 (STAT3). ... cancers, ISIS-STAT3Rx has the potential to be broadly useful ...
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
Cached Medicine Technology:Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 2Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 3Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 4Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4
(Date:7/31/2014)... Beverly Hills, CA (PRWEB) July 31, 2014 ... president George W. Bush recently underwent partial knee replacement surgery ... right knee less than two months earlier. The story also ... between the procedures and hopes to be back on the ... replacement surgery highlights the benefits of partial knee replacement. ...
(Date:7/31/2014)... 2014 Recognizing that today’s medical students ... Healthcare Conference announced today its student discount program. ... medicine or a healthcare-related field, as well as medical ... discounts for the conference, scheduled for September 17-20, 2014 ... Resort. , “As a future Registered Dietitian, ...
(Date:7/31/2014)... ProtonPACS, a division of Radsource, has signed ... Health Association (NRHA), company officials announced today. The partnership ... of rural health providers nationwide. , “We are proud ... Dr. Mark Awh, President of Radsource. “While we are ... are also looking forward to learning from all of ...
(Date:7/31/2014)... The shale gas development that has vaulted ... U.S. natural gas production has raised concerns that local ... similar to previous resource extraction experiences in Pennsylvania’s history. ... & Jefferson College’s (W&J) Center for Energy Policy & ... that the gas boom in Pennsylvania is still underway, ...
(Date:7/31/2014)... (August 1, 2014) While it is known that members ... use alcohol, a new study finds that female enlistees ... than their civilian counterparts. This study was published today ... journal published on behalf of the Inter-University Seminar on ... and Lucky Tedrow studied surveys of nearly 9,000 men ...
Breaking Medicine News(10 mins):Health News:George W. Bush’s Surgery Highlights the Benefits of Partial Knee Replacement 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 3Health News:ProtonPACS Announces Pipeline Partnership with the National Rural Health Association. 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 3Health News:Women in military less likely to drink than civilian women 2
... James "Buster" Douglas, former World Heavyweight Boxing Champion, ... brand new inspirational diabetic diet cookbook. "Take a ... Bar-B-Q Knockout Diabetes Diet," available now on Amazon.com ... to order for Mother,s Day, Sunday, May 10, ...
... Partners, Inc. and its affiliate, JLL Patheon Holdings, LLC (collectively, ... on May 7, 2009 (the "Expiry Time") 31,411,927 Restricted Voting ... deposited to JLL,s offer to acquire, at a price of ... and outstanding Restricted Voting Shares of Patheon (the "Offer"). As ...
... Universal Capital Management, Inc. (OTC Bulletin Board: UCMT), ... management and strategic growth resources to emerging growth ... ("Vystar") and Alatech Healthcare, LLC announced 510(k) clearance ... to market and sell Alatech,s Envy(TM) condom manufactured ...
... less cardiovascular disease than those who smoke, according ... and women in Norway. Smoking, say the investigators, ... from various causes. , The results, presented in ... studies have indicated, but, says investigator Professor Haakon ...
... preventive measures identified by the European Heart Health ... of EuroPRevent 2009, the congress of the European ... takes place in Stockholm, Sweden, on 6-9 May. ... is shown to improve markers of heart disease ...
... Netherlands: New research that uses an innovative approach to study, ... exercise habits to the development of the obesity epidemic has ... since the 1970s was virtually all due to increased energy ... has been caused by excess calorie intake and how much ...
Cached Medicine News:Health News:President Obama's New Knockout Mother's Day Message from Champ 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 3Health News:Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL 2Health News:Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL 3Health News:Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL 4Health News:30-year follow-up study: 'Tremendous' impact of smoking on mortality and cardiovascular disease 2Health News:More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure 2Health News:More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure 3Health News:Increased food intake alone explains the increase in body weight in the United States 2Health News:Increased food intake alone explains the increase in body weight in the United States 3
Printed with large 20/200 E on one side and a series of five 20/20 tumbling Es on the other- calibrated to a 20 ft. distance. May be used to test and train peripheral awareness....
... 2/25 is an economically priced 2-channel ... and research use in the fields ... neurophysiology, biology, zoology, biochemistry and biomedical ... ADInstruments signal conditioners and transducers. Two ...
... The PowerLab/4SP is a high-performance data ... of research applications including human and animal ... biomedical engineering. The unit is capable of ... speeds (up to 200 000 samples per ...
... Worth 4 Dot with 955R Red/Green ... the presence of binocular vision. Consists ... illuminated discs: two green, one red ... at any distance. Patient wears red/green ...
Medicine Products: